Rocuronium Bromide

119302-91-9

C32H53BrN2O4

609.68

Off-white to yellowish powder

Soluble in water, ethanol, and DMSO

Source: Synthetic
Purity Level: ≥99-101% (anhydrous basis)

≤30°C

Eukaryotic Cell Culture Applications: In the first study of the genotoxic effects of Rocuronium Bromide, human peripheral blood lymphocytes were exposed to Rocuronium Bromide (60, 80 and 100 µg/mL) and analyses included sister chromatid exchange, chromosome aberration, and micronucleus analyses were done. This model is an extremely sensitive indicator of in vitro and in vivo-induced chromosome structural change. Findings from this study suggest that Rocuronium Bromide is clastogenic (induces chromosome aberrations) but not cytotoxic to cultured human peripheral blood lymphocytes at concentrations studied (Zan et al, 2011).
The effect of Rocuronium on formation of main diazepam metabolites in primary culture of human hepatocytes has been examined. It inhibited formation of temazepam (by CYP3A4) by 20% and inhibited formation of nordiazepam (by CYP2C19) by 15%. Thus, interactions of Rocuronium with drugs metabolized by CYP3A4 and CYP2C19 may be observed (Anzenbacherova et al, 2015).
The effect of Rocuronium binding to m1-m5 recombinant muscarinic receptors stably expressed in Chinese hamster ovary (CHO) cells was examined. Parameters measured included methacholine inhibition and cyclic AMP formation. Authors found that Rocuronium did not to interact with muscarinic receptors at the concentration used (1 µM) unlike other neuromuscular blocking agents used in the study (pancuronium, vercuronium, pipercuronium and gallamine) where there was a significant interaction with m2 muscarinic receptors (Cembala et al, 1998).